International Journal of Diabetes and Endocrinology

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

High Lipoprotein (a) Concentration Is Associated with Diabetic Nephrophaty

Aims: Lipoprotein (a) [Lp(a)] has been well recognized as a risk factor for both micro and macrovascular complications in diabetes, due to its atherogenic effects. Studies suggested that serum lipoprotein (a) [Lp(a)] concentration may take part in the aggravation of diabetic nephropathy. Accumulating evidence suggests that higher serum Lp(a) may be associated with impaired renal function in populations. Therefore this study comprehensively evaluates the association between Lipoprotein (a) and diabetic nephropathy in patients with type 2 diabetes mellitus. Methods: One hundred subjects (50 with diabetic nephrophaty and 50 type 2 diabetes mellitus without nephrophaty) were studied. The examination used blood serum where lipoprotein a used the ELISA method. Nonpara- metric Mann–Whitney U-tests were used to compare the levels of lipoprotein a in diabetic nephrophaty and Type 2 DM without diabetic nephropathy. Results: Lipoprotein a in the diabetic nephropathy group was higher when compared to the type 2 DM group without nephropathy (OR = 2.8; 95%; CI = 1.84-12.07). Conclution: High lipoprotein (a) concentration are associated with diabetic nephrophaty. Lipoprotein may reflect chronic underlying pathophysiological processes involved in development of complications of T2DM and serum Lp(a) can be considered as a promising predictive factor for the diagnosis of earlier diabetic nephropathy.

Lipoprotein (a), Diabetic Nephrophaty, Type 2 Diabetes Mellitus

APA Style

Meutia Atika Faradilla, Karina Shasri Anastasya, Yohana, Meiyanti, Andira Larasari, et al. (2023). High Lipoprotein (a) Concentration Is Associated with Diabetic Nephrophaty. International Journal of Diabetes and Endocrinology, 8(3), 37-41. https://doi.org/10.11648/j.ijde.20230803.11

ACS Style

Meutia Atika Faradilla; Karina Shasri Anastasya; Yohana; Meiyanti; Andira Larasari, et al. High Lipoprotein (a) Concentration Is Associated with Diabetic Nephrophaty. Int. J. Diabetes Endocrinol. 2023, 8(3), 37-41. doi: 10.11648/j.ijde.20230803.11

AMA Style

Meutia Atika Faradilla, Karina Shasri Anastasya, Yohana, Meiyanti, Andira Larasari, et al. High Lipoprotein (a) Concentration Is Associated with Diabetic Nephrophaty. Int J Diabetes Endocrinol. 2023;8(3):37-41. doi: 10.11648/j.ijde.20230803.11

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. N. M. Selby and M. W. Taal, “An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines,” Diabetes Obes Metab, vol. 22, pp. 3–15, 2020.
2. M. K. Sulaiman, “Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management,” Diabetol Metab Syndr, vol. 11, pp. 1–5, 2019.
3. K. Umanath and J. B. Lewis, “Update on diabetic nephropathy: core curriculum 2018,” American journal of kidney diseases, vol. 71, no. 6, pp. 884–895, 2018.
4. X.-X. Zhang, J. Kong, and K. Yun, “Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies,” J Diabetes Res, vol. 2020, 2020.
5. N. Nowak, “Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: from current human evidence to future possibilities,” J Diabetes Investig, vol. 11, no. 5, pp. 1085–1096, 2020.
6. C. Lamina and N. C. Ward, “Lipoprotein (a) and diabetes mellitus,” Atherosclerosis, vol. 349, pp. 63–71, 2022, doi: https://doi.org/10.1016/j.atherosclerosis.2022.04.016.
7. S. Tsimikas, “A test in context: lipoprotein (a) diagnosis, prognosis, controversies, and emerging therapies,” J Am Coll Cardiol, vol. 69, no. 6, pp. 692–711, 2017.
8. D. P. Wilson, M. L. Koschinsky, and P. M. Moriarty, “Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein (a),” Curr Opin Endocrinol Diabetes Obes, vol. 28, no. 2, pp. 159–173, 2021.
9. J. C. Hopewell, R. Haynes, and C. Baigent, “The role of lipoprotein (a) in chronic kidney disease: thematic review series: lipoprotein (a): coming of age at last,” J Lipid Res, vol. 59, no. 4, pp. 577–585, 2018.
10. J. Lin, M. P. Reilly, K. Terembula, and F. P. Wilson, “Plasma lipoprotein (a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria,” PLoS One, vol. 9, no. 12, p. e114397, 2014.
11. H. Senba et al., “Serum lipoprotein (a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus,” J Diabetes Complications, vol. 30, no. 5, pp. 923–927, 2016.
12. J. Yun et al., “Lipoprotein (a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus,” Diabetic Medicine, vol. 33, no. 5, pp. 639–643, 2016.
13. F. Moosaie et al., “Lp (a) and Apo-lipoproteins as predictors for micro-and macrovascular complications of diabetes: A case-cohort study,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 30, no. 10, pp. 1723–1731, 2020.
14. P. Muraliswaran, G. Aparna, P. Kanagavalli, and S. Srikanth, “Association between Microalbuminuria and HbA1C among known Type 2 Diabetic patients in puducherry population-A comparative study,” IOSR J Biotechnol Biochem, vol. 2, no. 6, pp. 15–17, 2016.
15. K. Riches and K. E. Porter, “Lipoprotein (a): cellular effects and molecular mechanisms,” Cholesterol, vol. 2012, 2012.
16. M. A. Faradilla, Y. Siregar, and D. Dalimunthe, “Penurunan Bilirubin Meningkatkan Oksidasi Lipoprotein A Pada Nefropati Diabetik,” Jurnal Kedokteran Syiah Kuala, vol. 17, no. 3, pp. 152–158, 2017.
17. R. Toro, E. Segura, J. M. Nuñez-Cortes, J. C. Pedro-Botet, M. Quezada-Feijoo, and A. Mangas, “Relationship between lipoprotein (a) and micro/macro complications in type 2 diabetes mellitus: a forgotten target,” J Geriatr Cardiol, vol. 12, no. 2, p. 93, 2015.
18. S. Rosas, M. Joffe, M. Wolfe, K. Brayman, and D. J. Rader, “Effects of renal replacement therapy on plasma lipoprotein (a) levels,” Am J Nephrol, vol. 28, no. 3, pp. 361–365, 2008.
19. F. Kronenberg, “Causes and consequences of lipoprotein (a) abnormalities in kidney disease,” Clin Exp Nephrol, vol. 18, pp. 234–237, 2014.
20. C.-C. Hung, J.-C. Tsai, H.-T. Kuo, J.-M. Chang, S.-J. Hwang, and H.-C. Chen, “Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials,” Rev Diabet Stud, vol. 10, no. 2–3, p. 110, 2013.
21. S. Greiber, A. Krämer-Guth, H. Pavenstädt, M. Gutenkunst, P. Schollmeyer, and C. Wanner, “Effects of lipoprotein (a) on mesangial cell proliferation and viability,” Nephrology Dialysis Transplantation, vol. 11, no. 5, pp. 778–785, 1996.
22. U. F. Mondorf et al., “Lipoprotein (a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins,” Kidney Int, vol. 55, no. 4, pp. 1359–1366, 1999.
23. A. Charlton, J. Garzarella, K. A. M. Jandeleit-Dahm, and J. C. Jha, “Oxidative stress and inflammation in renal and cardiovascular complications of diabetes,” Biology (Basel), vol. 10, no. 1, p. 18, 2020.
24. P. R. Hansen, A. Kharazmi, M. Jauhiainen, and C. Ehnholm, “Induction of oxygen free radical generation in human monocytes by lipoprotein (a),” Eur J Clin Invest, vol. 24, no. 7, pp. 497–499, 1994.
25. E. Orsó and G. Schmitz, “Lipoprotein (a) and its role in inflammation, atherosclerosis and malignancies,” Clin Res Cardiol Suppl, vol. 12, pp. 31–37, 2017.